Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Brain Neoplasms 2Neoplasm Metastasis 1Glioma 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 20Radiosurgery 15Magnetic Resonance Spectroscopy 15Capecitabine 14Lapatinib 12Radiotherapy 11Specimen Handling 10Cyclophosphamide 9trastuzumab deruxtecan 8Temozolomide 8Docetaxel 8Paclitaxel 7Gemcitabine 6Cisplatin 6sacituzumab govitecan 5Vinorelbine 5Therapeutics 5Spinal Puncture 5Flow Cytometry 5tucatinib 4pembrolizumab 4paclitaxel-Angiopep-2 conjugate 4eribulin 4Methotrexate 4Irinotecan 4Fluorodeoxyglucose F18 4Dexamethasone 4Bevacizumab 4temsirolimus 3pyrotinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × peginterferon alfa-2a × CNS × Clear all
NCT00227656 2012-12-11

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡